BR112014028130A2 - Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos - Google Patents

Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos

Info

Publication number
BR112014028130A2
BR112014028130A2 BR112014028130A BR112014028130A BR112014028130A2 BR 112014028130 A2 BR112014028130 A2 BR 112014028130A2 BR 112014028130 A BR112014028130 A BR 112014028130A BR 112014028130 A BR112014028130 A BR 112014028130A BR 112014028130 A2 BR112014028130 A2 BR 112014028130A2
Authority
BR
Brazil
Prior art keywords
hydrochloride salt
pharmaceutical composition
peptide
preventing
cat allergy
Prior art date
Application number
BR112014028130A
Other languages
English (en)
Portuguese (pt)
Inventor
Laidler Paul
Farkas Imre
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of BR112014028130A2 publication Critical patent/BR112014028130A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112014028130A 2012-05-11 2013-05-09 Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos BR112014028130A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201208293A GB201208293D0 (en) 2012-05-11 2012-05-11 Hydrochlorice salt of peptide
PCT/GB2013/051201 WO2013167897A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

Publications (1)

Publication Number Publication Date
BR112014028130A2 true BR112014028130A2 (pt) 2017-08-15

Family

ID=46396890

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028130A BR112014028130A2 (pt) 2012-05-11 2013-05-09 Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos

Country Status (17)

Country Link
US (1) US9657061B2 (enExample)
EP (1) EP2847209B8 (enExample)
JP (1) JP5982562B2 (enExample)
KR (1) KR20150014955A (enExample)
CN (1) CN104428311B (enExample)
AU (1) AU2013257784A1 (enExample)
BR (1) BR112014028130A2 (enExample)
CA (1) CA2873120A1 (enExample)
EA (1) EA201492068A1 (enExample)
GB (2) GB201208293D0 (enExample)
HK (1) HK1201850A1 (enExample)
IL (1) IL235388A (enExample)
IN (1) IN2014DN09367A (enExample)
MX (1) MX2014013394A (enExample)
SG (1) SG11201407446TA (enExample)
WO (1) WO2013167897A1 (enExample)
ZA (1) ZA201408290B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20211754T1 (hr) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
DK3388075T5 (da) 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
WO2021038431A1 (en) * 2019-08-26 2021-03-04 Auro Peptides Ltd An improved process for the preparation of etelcalcetide hydrochloride
WO2021137160A1 (en) * 2019-12-31 2021-07-08 Pfizer R&D Uk Limited Stable immediate release tablet and capsule formulations of 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
TWI792442B (zh) * 2021-07-23 2023-02-11 建誼生技股份有限公司 依特卡肽鹽酸鹽之製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453539B1 (en) * 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
MX2008009125A (es) 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
DK2083856T3 (da) * 2007-08-15 2011-01-24 Circassia Ltd Peptider til desensibilisering mod allergener
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CA2795047C (en) * 2010-03-31 2019-04-09 Stabilitech Ltd. Stabilised liquid formulations

Also Published As

Publication number Publication date
GB201421491D0 (en) 2015-01-14
JP5982562B2 (ja) 2016-08-31
GB201208293D0 (en) 2012-06-20
KR20150014955A (ko) 2015-02-09
EA201492068A1 (ru) 2015-03-31
EP2847209B1 (en) 2020-08-05
CN104428311A (zh) 2015-03-18
EP2847209A1 (en) 2015-03-18
IL235388A (en) 2016-06-30
ZA201408290B (en) 2016-01-27
AU2013257784A1 (en) 2014-11-20
GB2517354A (en) 2015-02-18
CN104428311B (zh) 2019-11-01
WO2013167897A1 (en) 2013-11-14
HK1201850A1 (en) 2015-09-11
JP2015517484A (ja) 2015-06-22
IN2014DN09367A (enExample) 2015-07-17
CA2873120A1 (en) 2013-11-14
MX2014013394A (es) 2015-02-04
EP2847209B8 (en) 2020-10-07
SG11201407446TA (en) 2015-03-30
US9657061B2 (en) 2017-05-23
US20150110820A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
UA118167C2 (uk) Пептид та його застосування
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CO2017005995A2 (es) Composiciones para el cuidado bucal y métodos de uso
MX370924B (es) Composiciones para modular la expresión de c9orf72.
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
EP4414376A3 (en) Novel depsipeptide and uses thereof
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
BR112013003722A2 (pt) produtos para cuidado e métodos de uso e fabricação dos mesmos
BR112014025041B8 (pt) Composição farmacêutica
BR112015001096A2 (pt) derivados de di e tri-heteroaril como inibidores de agregação de proteína
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
BR112015018265A2 (pt) Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
BR112013024265A2 (pt) peptídeo cíclico, uso de peptídeos cíclicos, método para o tratamento de doenças, composição farmacêutica, composto para o diagnóstico de câncer, e, combinação farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]